Assessment of a New ROS 1 Immunohistochemistry Clone ( SP 384 ) for the Identification of ROS 1 Rearrangements in Non-Small Cell Lung Carcinoma Patients : the ROSING Study Running title : ROS 1 Immnunohistochemistry with clone SP 384
暂无分享,去创建一个
J. Mate | M. Salido | E. Felip | F. Rojo | I. Abdulkader | N. Reguart | B. Massuti | A. Collazo-Lorduy | I. Aranda | A. Muriel | M. Lozano | T. Morán | J. Castro | J. González-Larriba | E. Arriola | L. Pijuan | E. Conde | J. Sanz | C. Teixidó | I. Sansano | S. Hernández | R. Martínez | Barbara | Angulo | B. Jiménez | Felip García | N. Mancheño | S. Hernandez
[1] C. Marquette,et al. Multicenter Evaluation of a Novel ROS1 Immunohistochemistry Assay (SP384) for Detection of ROS1 Rearrangements in a Large Cohort of Lung Adenocarcinoma Patients. , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[2] M. Hellmich,et al. Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial. , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[3] M. Salido,et al. Next-generation Sequencing for ALK and ROS1 Rearrangement Detection in Patients With Non-small-cell Lung Cancer: Implications of FISH-positive Patterns. , 2019, Clinical lung cancer.
[4] N. Girard,et al. Advanced-Stage Non-Small Cell Lung Cancer: Advances in Thoracic Oncology 2018. , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[5] M. Ladanyi,et al. High Yield of RNA Sequencing for Targetable Kinase Fusions in Lung Adenocarcinomas with No Mitogenic Driver Alteration Detected by DNA Sequencing and Low Tumor Mutation Burden , 2019, Clinical Cancer Research.
[6] A. Nicholson,et al. MA26.07 ROS1 (SP384) Immunohistochemistry Inter-Reader Precision Between 12 Pathologists , 2018, Journal of Thoracic Oncology.
[7] L. Sholl. Recognizing the Challenges of Oncogene Fusion Detection: A Critical Step toward Optimal Selection of Lung Cancer Patients for Targeted Therapies. , 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[8] I. Menzl,et al. P2.09-13 Correlation of ROS1 (SP384) Immunohistochemistry with ROS1 Rearrangement Determined by Fluorescence in Situ Hybridization , 2018, Journal of Thoracic Oncology.
[9] J. Ahn,et al. Characteristics and Outcome of ROS1‐Positive Non–Small Cell Lung Cancer Patients in Routine Clinical Practice , 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[10] J. Zhao,et al. A genomic and clinicopathological study of non‐small‐cell lung cancers with discordant ROS1 gene status by fluorescence in‐situ hybridisation and immunohistochemical analysis , 2018, Histopathology.
[11] Jia Huang,et al. Efficacy of Crizotinib among Different Types of ROS1 Fusion Partners in Patients with ROS1‐Rearranged Non–Small Cell Lung Cancer , 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[12] T. Yamanaka,et al. Phase II Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non-Small-Cell Lung Cancer. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] Benjamin Solomon,et al. Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology , 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[14] A. Shaw,et al. Lorlatinib in ALK- or ROS1-rearranged non-small cell lung cancer: an international, multicenter, open-label phase 1 trial , 2017, The Lancet. Oncology.
[15] Kenneth L. Jones,et al. Comparison of Molecular Testing Modalities for Detection of ROS1 Rearrangements in a Cohort of Positive Patient Samples , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[16] A. Shaw,et al. Recent Advances in Targeting ROS1 in Lung Cancer , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[17] R. Franco,et al. Detection of ROS1 rearrangement in non-small cell lung cancer: current and future perspectives , 2017, Lung Cancer.
[18] M. Ahn,et al. Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non-Small-Cell Lung Cancer Harboring ROS1 Rearrangement. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] L. Bubendorf,et al. Lonely Driver ROS1. , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[20] Lauren L. Ritterhouse,et al. ROS1 Fusions Rarely Overlap with Other Oncogenic Drivers in Non–Small Cell Lung Cancer , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[21] A. Drilon,et al. Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1). , 2017, Cancer discovery.
[22] N. Pavlakis,et al. Screening for ROS1 gene rearrangements in non‐small‐cell lung cancers using immunohistochemistry with FISH confirmation is an effective method to identify this rare target , 2017, Histopathology.
[23] E. Gabrielson,et al. Heterogeneous expression of PD-L1 in pulmonary squamous cell carcinoma and adenocarcinoma: implications for assessment by small biopsy , 2017, Modern Pathology.
[24] D. Dias-Santagata,et al. Immunohistochemical Detection of ROS1 Fusion , 2016, American journal of clinical pathology.
[25] K. Kerr,et al. Precision medicine in NSCLC and pathology: how does ALK fit in the pathway? , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.
[26] A. Marchetti,et al. Review and Perspectives , 2022 .
[27] S. Sabour. Reliability Assurance of EML4-ALK Rearrangement Detection in Non-Small Cell Lung Cancer: A Methodological and Statistical Issue. , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[28] A. Nicholson,et al. A Validation Study for the Use of ROS1 Immunohistochemical Staining in Screening for ROS1 Translocations in Lung Cancer , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[29] S. Fox,et al. Comparison of Methods in the Detection of ALK and ROS1 Rearrangements in Lung Cancer , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[30] Roman K. Thomas,et al. Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] Dongmei Lin,et al. Detection of ROS1 Gene Rearrangement in Lung Adenocarcinoma: Comparison of IHC, FISH and Real-Time RT-PCR , 2015, PloS one.
[32] K. Arnaoutakis. Crizotinib in ROS1-rearranged non-small-cell lung cancer. , 2015, The New England journal of medicine.
[33] F. Hirsch,et al. ROS1 Immunohistochemistry Among Major Genotypes of Non—Small-Cell Lung Cancer , 2014, Clinical lung cancer.
[34] E. Mahé. Comment on ‘Testing for ALK rearrangement in lung adenocarcinoma: a multicenter comparison of immunohistochemistry and fluorescent in situ hybridization’ , 2014, Modern Pathology.
[35] M. Salido,et al. Accurate Identification of ALK Positive Lung Carcinoma Patients: Novel FDA-Cleared Automated Fluorescence In Situ Hybridization Scanning System and Ultrasensitive Immunohistochemistry , 2014, PloS one.
[36] A. Warth,et al. ROS1 expression and translocations in non‐small‐cell lung cancer: clinicopathological analysis of 1478 cases , 2014, Histopathology.
[37] T. Kohno,et al. Immunohistochemical detection of ROS1 is useful for identifying ROS1 rearrangements in lung cancers , 2014, Modern Pathology.
[38] E. Brambilla,et al. On the relevance of a testing algorithm for the detection of ROS1-rearranged lung adenocarcinomas. , 2014, Lung cancer.
[39] P. Jänne,et al. ROS1 Immunohistochemistry for Detection of ROS1-Rearranged Lung Adenocarcinomas , 2013, The American journal of surgical pathology.
[40] A. Shaw,et al. Novel targets in non-small cell lung cancer: ROS1 and RET fusions. , 2013, The oncologist.
[41] T. Kohno,et al. ROS1-Rearranged Lung Cancer: A Clinicopathologic and Molecular Study of 15 Surgical Cases , 2013, The American journal of surgical pathology.
[42] Tatsuo Ito,et al. Identification of KIF5B-RET and GOPC-ROS1 Fusions in Lung Adenocarcinomas through a Comprehensive mRNA-Based Screen for Tyrosine Kinase Fusions , 2012, Clinical Cancer Research.
[43] K. Darwiche,et al. High Prevalence of Concomitant Oncogene Mutations in Prospectively Identified Patients with ROS1‐Positive Metastatic Lung Cancer , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.